Teva's US exclusive-dealing claims survive Corcept's move to dismiss
( May 5, 2026, 23:03 GMT | Official Statement) -- MLex Summary: Teva's antitrust claims that Corcept Therapeutics developed and implemented illegal exclusive-dealing arrangements can advance, a California federal judge ruled. In an order partially denying Corcept and Optime Care's motion to dismiss, US District Judge Noël Wise said that at this stage in the litigation, Teva "has adequately alleged that Defendants’ agreements substantially foreclose competition." See court's order. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.